

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Cefalexin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised againstUse of the Sub-
stance/Mixture : Veterinary productRecommended restrictions
on use : Not applicable**1.3 Details of the supplier of the safety data sheet**Company : MSD
20 Spartan Road
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com**1.4 Emergency telephone number**

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Respiratory sensitisation, Category 1	H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Reproductive toxicity, Category 2	H361f: Suspected of damaging fertility.
Specific target organ toxicity - single exposure, Category 3	H335: May cause respiratory irritation.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Danger

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H335 May cause respiratory irritation.
H361f Suspected of damaging fertility.
H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

Hazardous components which must be listed on the label:

Cefalexin

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 21 %

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Cefalexin	15686-71-2 239-773-6	Acute Tox. 4; H302 Resp. Sens. 1A; H334 Repr. 2; H361f STOT SE 3; H335 STOT RE 2; H373 (Kidney, Adrenal gland, Blood, Gas- trointestinal tract)	>= 20 - < 30

For explanation of abbreviations see section 16.

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

SECTION 4: First aid measures**4.1 Description of first aid measures**

- | | |
|----------------------------|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | |
|-------|---|
| Risks | : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).

May cause allergy or asthma symptoms or breathing difficulties if inhaled.
May cause respiratory irritation.
Suspected of damaging fertility.
May cause damage to organs through prolonged or repeated exposure. |
|-------|---|

4.3 Indication of any immediate medical attention and special treatment needed

- | | |
|-----------|---|
| Treatment | : Treat symptomatically and supportively. |
|-----------|---|

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

SECTION 5: Firefighting measures**5.1 Extinguishing media**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Sulphur oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Gases |

Cefalexin Formulation

Version 2.0 Revision Date: 14.04.2025 SDS Number: 11474869-00002 Date of last issue: 26.11.2024
Date of first issue: 26.11.2024

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cefalexin	15686-71-2	TWA	550 µg/m3 (OEB 2)	Internal
Further information: RSEN				

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerides, mixed decanoyl and octanoyl	Workers	Inhalation	Long-term systemic effects	177,79 mg/m3
	Workers	Skin contact	Long-term systemic effects	25,21 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	43,84 mg/m3
	Consumers	Skin contact	Long-term systemic effects	12,61 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	12,61 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Glycerides, mixed decanoyl and octanoyl	Oral (Secondary Poisoning)	0,03 mg/kg food

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance	:	liquid
Colour	:	clear
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Molecular weight : No data available

Particle size : Not applicable

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:**Cefalexin:**

|| Acute oral toxicity : LD50 (Mouse): 1.600 - 6.200 mg/kg
LD50 (Dog): > 2.000 mg/kg
Symptoms: Vomiting

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

Acute toxicity (other routes of administration)	LD50 (Monkey): > 1.000 mg/kg
	Symptoms: Vomiting
	LD50 (Rat): > 20.000 mg/kg
	LD50 (Dog): > 1 g/kg
	Application Route: Intraperitoneal
	LD50 (Dog): > 0,1 g/kg
	Application Route: Intravenous

Skin corrosion/irritation

|| Not classified based on available information.

Serious eye damage/eye irritation

|| Not classified based on available information.

Respiratory or skin sensitisation**Skin sensitisation**

|| Not classified based on available information.

Respiratory sensitisation

|| May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:**Cefalexin:**

Assessment	: Probability or evidence of high respiratory sensitisation rate in humans
Remarks	: Based on data from similar materials May cause sensitisation by inhalation.

Result	: Sensitiser
Remarks	: Based on data from similar materials May cause sensitisation by inhalation.

Germ cell mutagenicity

|| Not classified based on available information.

Components:**Cefalexin:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: Chromosomal aberration
	Test system: Chinese hamster ovary cells
	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Test system: mouse lymphoma cells
	Result: negative

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging fertility.

Components:**Cefalexin:**

Effects on fertility : Test Type: Two-generation study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 250 mg/kg body weight
Result: May cause adverse reproductive effects., Reduced fertility of F1 generation

Effects on foetal development : Test Type: Development
Species: Mouse
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 400 mg/kg body weight
Remarks: No significant adverse effects were reported
Maternal toxicity observed.

Test Type: Development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 1.200 mg/kg body weight
Remarks: No significant adverse effects were reported
Maternal toxicity observed.

Reproductive toxicity - Assessment : Suspected of damaging fertility.

STOT - single exposure

May cause respiratory irritation.

Components:**Cefalexin:**

Exposure routes : Inhalation
Assessment : May cause respiratory irritation.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:**Cefalexin:**

Target Organs : Kidney, Adrenal gland, Blood, Gastrointestinal tract
Assessment : May cause damage to organs through prolonged or repeated exposure.

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

Repeated dose toxicity**Components:****Cefalexin:**

Species	: Rat
NOAEL	: < 160 mg/kg
Application Route	: Oral
Target Organs	: Kidney, Adrenal gland, Blood
Symptoms	: Vomiting, Diarrhoea, Kidney disorders, Blood disorders

Species	: Dog
NOAEL	: < 160 mg/kg
Application Route	: Oral
Target Organs	: Kidney, Adrenal gland, Blood
Symptoms	: Vomiting, Diarrhoea, Blood disorders, Kidney disorders

Species	: Monkey
NOAEL	: < 160 mg/kg
Application Route	: Oral
Target Organs	: Kidney, Adrenal gland, Blood
Symptoms	: Vomiting, Diarrhoea, Blood disorders, Kidney disorders

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Cefalexin:**

Inhalation	: Target Organs: Respiratory Tract Remarks: May cause irritation of respiratory tract. May cause sensitisation by inhalation.
Ingestion	: Target Organs: Gastrointestinal tract Symptoms: The most common side effects are:, Nausea, Vomiting, Abdominal pain, Diarrhoea, liver function change, blood effects

SECTION 12: Ecological information**12.1 Toxicity****Components:****Cefalexin:****Ecotoxicology Assessment**

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : UN 3334

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Aviation regulated liquid, n.o.s.
II	:	(Cefalexin)

14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
		Class Subsidiary risks
IATA	:	9

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)		
Packing instruction (cargo aircraft)	:	964
Packing instruction (LQ)	:	Y964
Packing group	:	III
Labels	:	Miscellaneous
IATA (Passenger)		
Packing instruction (passenger aircraft)	:	964
Packing instruction (LQ)	:	Y964
Packing group	:	III
Labels	:	Miscellaneous

14.5 Environmental hazards

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks	:	Not applicable for product as supplied.
---------	---	---

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

DSL	:	not determined
AICS	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

Full text of H-Statements

H302	:	Harmful if swallowed.
H334	:	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H335	:	May cause respiratory irritation.
H361f	:	Suspected of damaging fertility.
H373	:	May cause damage to organs through prolonged or repeated exposure.

Full text of other abbreviations

Acute Tox.	:	Acute toxicity
Repr.	:	Reproductive toxicity
Resp. Sens.	:	Respiratory sensitisation
STOT RE	:	Specific target organ toxicity - repeated exposure
STOT SE	:	Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL

Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.11.2024
2.0	14.04.2025	11474869-00002	Date of first issue: 26.11.2024

- Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Resp. Sens. 1	H334
Repr. 2	H361f
STOT SE 3	H335
STOT RE 2	H373

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN